Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Participants must be willing to provide tumor tissue samples before treatment begins and again during treatment, for research testing.
- Participants must have measurable tumors that can be seen on scans, and at least one tumor that can be safely biopsied with a needle (note: fine needle, fluid cell, or bone biopsies are not accepted).
- Participants must have a good general level of physical function, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
- Scans must show that the cancer has continued to grow or spread during or after the most recent treatment received.
- Participants must have already received standard treatments for their cancer type, including an approved immunotherapy drug known to work for that cancer (with some exceptions around a specific chemotherapy drug called docetaxel, depending on which part of the trial is involved — confirm with trial site).
- Participants must have advanced or metastatic cancer and have already received, been unable to tolerate, not responded to, or been considered unsuitable for other treatments known to help their condition.
Who may not be able to join:
- People who are pregnant or breastfeeding.
- People whose cancer started in the brain or spinal cord.
- People who have cancer that has spread to the brain or spinal cord and has not yet been treated.
- People whose cancer has spread to the lining surrounding the brain and spinal cord.
- People who currently have another cancer requiring treatment, or who have had another active cancer within the past 2 years.
- People with an active, known, or suspected condition where the immune system attacks the body (autoimmune disease).
- People who need ongoing treatment with steroid medications (within the past 14 days) or other immune-suppressing medications (within the past 30 days) before starting the trial.
- People who have previously received a transplanted organ or tissue from another person.
- People with serious or poorly controlled heart or blood vessel disease.
- People who have had major surgery within 4 weeks before starting the trial drug.
- People with a history of, or currently having, scarring or inflammation of the lungs.
- Additional criteria set out in the trial protocol may also apply — confirm with trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+61 02 86705071
61287389744
61731765564
(03)95083434
61392313155
+61 08 6279 9466
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of adverse events (AEs); Incidence of serious adverse events (SAEs); Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria; Incidence of AEs leading to discontinuation; Number of deaths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.